Madrigal adopts 2023 Inducement Plan reserving 500,000 shares for new hires ahead of commercial launch

MADRIGAL PHARMACEUTICALS, INC.

Board adopted Inducement Plan on Sept 8, 2023, reserving 500,000 shares of common stock for equity grants.
Plan approved without stockholder approval per Nasdaq Listing Rule 5635(c)(4); only new employees eligible.
Plan supports expected substantial headcount increase as company prepares for commercial launch.
Administered by Compensation Committee; awards include options, RSUs, performance awards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.